切换至 "中华医学电子期刊资源库"
高级检索
中华消化病与影像杂志(电子版)

中华消化病与影像杂志(电子版) ›› 2024, Vol. 14 ›› Issue (05) : 413 -416. doi: 10.3877/cma.j.issn.2095-2015.2024.05.006

论著

参菝抗瘤液对结直肠腺瘤性息肉术后肠道功能、炎症指标及复发情况的影响
杭丽1, 张耀辉1,†(), 孙文恺1   
  1. 1. 215600　江苏省，南京中医药大学附属张家港市中医医院脾胃病科
  • 收稿日期:2024-01-03 出版日期:2024-10-01
  • 通信作者: 张耀辉

Effect of Shenba Kangliu Liquid on intestinal function, inflammatory index and recurrence after colorectal adenomatous polyp surgery

Li Hang1, Yaohui Zhang1,†(), Wenkai Sun1   

  1. 1. Department of Spleen and Stomach Diseases, Zhangjiagang Hospital of Traditional Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Zhangjiagang 215600, China
  • Received:2024-01-03 Published:2024-10-01
  • Corresponding author: Yaohui Zhang
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

杭丽, 张耀辉, 孙文恺. 参菝抗瘤液对结直肠腺瘤性息肉术后肠道功能、炎症指标及复发情况的影响[J]. 中华消化病与影像杂志(电子版), 2024, 14(05): 413-416.

Li Hang, Yaohui Zhang, Wenkai Sun. Effect of Shenba Kangliu Liquid on intestinal function, inflammatory index and recurrence after colorectal adenomatous polyp surgery[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(05): 413-416.

目的

分析参菝抗瘤液对结直肠腺瘤性息肉术后肠道功能、炎症指标及复发情况的影响。

方法

选取2021年1月至2022年9月张家港市中医医院收治的400例结直肠腺瘤性息肉患者，随机分为观察组（n=200）、对照组（n=200），2组均接受肠镜下息肉切除术治疗，观察组接受参菝抗瘤液治疗，持续2周。对比2组患者术后肠道功能恢复时间、肠壁恢复情况、血清炎症指标及复发率。

结果

2组患者术后肠鸣音恢复时间、首次进食时间、首次排便时间比较，差异无统计学意义（P>0.05）。2组患者术后14 d肠壁厚度、缺损长度、中性粒细胞计数（NEU）、中性粒细胞与淋巴细胞比值（NLR）、系统性免疫炎症指数（SII）均较术后1 d下降，淋巴细胞计数（LYM）均较术前1 d升高；观察组术后14 d肠壁厚度、缺损长度、NEU、NLR、SII均低于对照组，LYM高于对照组（P<0.05）。观察组术后6个月、1年复发率及总复发率均低于对照组（P<0.05）。

结论

参菝抗瘤液能够在不影响结直肠腺瘤性息肉患者术后肠道功能恢复的基础上，促进患者肠壁恢复、炎症指标改善，对降低术后短期复发率也有积极作用。

关键词: 结直肠腺瘤性息肉, 参菝抗瘤液, 肠道功能, 炎症指标, 复发
Objective

To analyze the effect of Shenba Kangliu Liquid on postoperative intestinal function, inflammatory indexes, and recurrence of colorectal adenomatous polyps.

Methods

A total of 400 patients with colorectal adenomatous polyps admitted to Zhangjiagang Hospital of Traditional Chinese Medicine from January 2021 to September 2022 were selected and randomly divided into an observation group (n=200) and a control group (n=200). Both groups underwent polypectomy under colonoscopy, while the observation group received Shenba Kangliu Liquid treatment for 2 weeks. The recovery time of intestinal function, the restoration of intestinal wall, serum inflammatory indexes and recurrence rate between the two groups were compared.

Results

There were no statistically significant differences in the recovery time of bowel sounds, time to initiate eating, and time to first defecation between the two groups (P>0.05). The thickness of the intestinal wall, the length of the defect, neutrophil count (NEU), neutrophil to lymphocyte ratio (NLR) and systemic immune inflammatory index (SII) decreased in both groups on the 14th day after the operation compared to the 1st day after the operation, while lymphocyte count (LYM) increased. Furthermore, on the 14th day after the operation, the thickness of the intestinal wall, the length of the defect, NEU, NLR, and SII in the observation group were lower than those in the control group (P<0.05), while LYM was higher than that in the control group (P<0.05). The 6-month and 1-year recurrence rates and the total recurrence rate of the observation group were lower than those of the control group (P<0.05).

Conclusion

Shenba Kangliu Liquid can promote the recovery of the intestinal wall and the improvement of inflammatory indexes in patients with colorectal adenomatous polyps without affecting the recovery of intestinal function after the operation. It also has a positive effect on reducing the recurrence rate at 6 months and 1 year after the operation.

Key words: Colorectal adenomatous polyp, Shenba Kangliu Liquid, Intestinal function, Inflammation index, Recurrence
表1 2组患者临床资料比较
组别 例数 年龄(岁,±s) 性别[例(%)] 病变部位[例(%)] 瘤变分级[例(%)]
男 女 结肠 直肠 低级别 高级别
观察组 200 54.69±7.17 117(58.50) 83(41.50) 143(71.50) 57(28.50) 107(53.50) 93(46.50)
对照组 200 55.02±7.26 121(60.50) 79(39.50) 147(73.50) 53(26.50) 112(56.00) 88(44.00)
t/χ2值   0.457 0.166 0.201 0.252
P值   0.648 0.684 0.654 0.615
表2 2组患者术后肠道功能恢复时间比较（h，±s）
组别 例数 肠鸣音恢复 首次进食时间 首次排便时间
观察组 200 15.68±3.51 20.81±4.62 28.71±6.83
对照组 200 15.74±3.66 21.15±4.33 28.59±6.46
t值   0.167 0.759 0.181
P值   0.867 0.448 0.857
表3 2组患者术后肠壁恢复情况比较（mm，±s）
组别 例数 肠壁厚度 缺损长度
术后1 d 术后14 d 术后1 d 术后14 d
观察组 200 9.81±1.33 3.11±0.56* 13.15±2.06 1.92±0.33*
对照组 200 9.79±1.25 6.03±0.78* 12.98±1.87 6.71±0.85*
t值   0.155 43.006 0.864 74.293
P值   0.877 <0.001 0.388 <0.001
表4 2组患者血清炎症指标变化比较（±s）
组别 例数 NEU(×109/L) PLT(×109/L) LYM(×109/L)
术前1 d 术后14 d 术前1 d 术后14 d 术前1 d 术后14 d
观察组 200 3.87±0.71 2.81±0.35* 238.78±16.29 236.14±15.34 1.63±0.23 2.03±0.39*
对照组 200 3.92±0.63 3.34±0.41* 239.66±17.55 237.48±18.03 1.65±0.22 1.84±0.31*
t值   0.745 13.904 0.520 0.801 0.889 5.393
P值   0.457 <0.001 0.604 0.424 0.375 <0.001
组别 例数 MON(×109/L) NLR SII
术前1 d 术后14 d 术前1 d 术后14 d 术前1 d 术后14 d
观察组 200 0.33±0.09 0.34±0.05 2.37±0.45 1.38±0.23* 566.92±71.45 321.34±34.51*
对照组 200 0.32±0.08 0.33±0.07 2.38±0.47 1.82±0.36* 569.37±68.66 427.45±42.66*
t值   1.174 1.644 0.217 14.566 0.350 27.348
P值   0.241 0.101 0.828 <0.001 0.727 <0.001
表5 2组患者术后复发率比较[例（%）]
组别 例数 术后6个月复发率 术后1年复发率 总复发率
观察组 200 4(2.00) 9(4.50) 13(6.50)
对照组 200 15(7.50) 24(12.00) 39(19.50)
χ2值   6.686 7.431 14.943
P值   0.010 0.006 <0.001
[1]
Schoen RE, Boardman LA, Cruz-Correa M, et al. Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma[J]. Clin Cancer Res, 2023, 29(9): 1678-1688.
[2]
Dang DT, Suresh S, Vance RB, et al. Outcomes of cold snare piecemeal EMR for nonampullary small-bowel adenomas larger than 1 cm: a retrospective study[J]. Gastrointest Endosc, 2022, 95(6): 1176-1182.
[3]
齐蕊, 吕书勤. 腺瘤性结直肠息肉术后复发的研究进展[J]. 新疆中医药, 2020, 38(2): 100-103.
[4]
潘迎英, 许纯. 参菝抗瘤液联合化疗治疗晚期胃癌的临床观察[J]. 世界中医药, 2017, 12(2): 362-365.
[5]
Chen YX, Gao QY, Zou TH, et al. Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study[J]. Lancet Gastroenterol Hepatol, 2020, 5(3): 267-275.
[6]
Yoshida N, Ishikawa H, Otani T, et al. Aspirin-mediated prevention of colorectal adenomas recurrence is affected by blood biochemistry and nutritional intake[J]. Cancer Prev Res, 2022, 15(12): 837-846.
[7]
蔡升, 褚建锋, 周建波, 等. 内镜下切除结直肠腺瘤性息肉的疗效及预后评估[J]. 温州医科大学学报, 2021, 51(3): 237-239, 243.
[8]
Gibbs DC, Barry EL, Fedirko V, et al. Impact of common vitamin D–binding protein isoforms on supplemental vitamin D3 and/or calcium effects on colorectal adenoma recurrence risk: a secondary analysis of a randomized clinical trial[J]. JAMA Oncol, 2023, 9(4): 546-551.
[9]
Pohl H, Anderson J C, Aguilera-Fish A, et al. Recurrence of colorectal neoplastic polyps after incomplete resection[J]. Ann Intern Med, 2021, 174(10): 1377-1384.
[10]
兰琴, 魏玉霞. 影响结肠腺瘤发病的危险因素及预防术后复发研究进展[J]. 中国中西医结合消化杂志, 2021, 29(8): 595-598.
[11]
Ishikawa H, Mutoh M, Sato Y, et al. Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy(J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial[J]. Lancet Gastroenterol Hepatol, 2021, 6(6): 474-481.
[12]
李盼盼, 贾玉萍, 吴瑞, 等. 基于多参数MRI影像组学模型预测直肠腺瘤癌变的研究[J/OL]. 中华消化病与影像杂志(电子版), 2021, 11(3): 111-116.
[13]
李忠意, 朱传旺, 商竞宇, 等. 民族药三子方防治腺瘤性大肠息肉术后复发的临床观察[J]. 中国中西医结合消化杂志, 2022, 30(7): 500-504.
[14]
Liang J Q, Zeng Y, Kwok G, et al. Novel microbiome signatures for non-invasive diagnosis of adenoma recurrence after colonoscopic polypectomy[J]. Aliment Pharm Ther, 2022, 55(7): 847-855.
[15]
许纯, 刘莲芳, 陶敏贤, 等. 参菝抗瘤液对人胃癌细胞株BGC-823及化疗药物协同作用研究[J]. 湖北中医药大学学报, 2016, 18(6): 10-13.
[16]
杨晓金, 李婷, 蔡波尔, 等. 五个家族性腺瘤性息肉病家系分析[J/OL]. 中华消化病与影像杂志(电子版), 2022, 12(4): 220-223.
[17]
刘莲芳, 许纯, 潘迎英. 基于健脾活血法探讨参菝抗瘤液对人胃癌SGC-7901裸鼠异种移植瘤的抑制作用研究[J]. 福建中医药, 2019, 50(4): 29-32.
[18]
Chang JJ, Chien CH, Chen SW, et al. Long term outcomes of colon polyps with high grade dysplasia following endoscopic resection[J]. BMC Gastroenterol, 2020, 20(1): 1-8.
[19]
Soualy A, Deutsch D, Benallaoua M, et al. Effect of chemoprevention by low-dose aspirin of new or recurrent colorectal adenomas in patients with Lynch syndrome(AAS-Lynch): study protocol for a multicenter, double-blind, placebo-controlled randomized controlled trial[J]. Trials, 2020, 21(1): 1-8.
[20]
Fiedler D, Hirsch D, El Hajj N, et al. Genome-wide DNA methylation analysis of colorectal adenomas with and without recurrence reveals an association between cytosine-phosphate-guanine methylation and histological subtypes[J]. Genes Chromosomes Cancer, 2019, 58(11): 783-797.
[1] 张少华, 林爱齐, 张玉, 董晓云, 刘红英. HLA和IL基因多态性及其与复发性自然流产的相关性[J]. 中华妇幼临床医学杂志(电子版), 2024, 20(03): 251-259.
[2] 张钊, 骆成玉, 张树琦, 何平, 李旭斌. 不同术式治疗早期乳腺癌的效果及并发症发生率、复发率比较[J]. 中华普外科手术学杂志(电子版), 2024, 18(05): 494-497.
[3] 曾繁利, 齐秩凯, 杨贺庆. 两种经Glisson蒂鞘解剖路径肝切除术治疗原发性肝癌的肿瘤学疗效及风险比对[J]. 中华普外科手术学杂志(电子版), 2024, 18(05): 525-527.
[4] 高建新, 王啸飞, 于淼, 路夷平. 局部进展期直肠癌新辅助治疗后行ISR术远切缘距离的临床研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(05): 539-543.
[5] 丁志翔, 于鹏, 段绍斌. 血浆BRAF基因检测对腹腔镜右半结肠癌D3根治术中行幽门淋巴结清扫的指导价值[J]. 中华普外科手术学杂志(电子版), 2024, 18(05): 570-573.
[6] 达热拜·热达提, 刘林, 赵为民, 孟涛, 雷程, 金博, 毕建军, 李新宇, 王海江. 中低位直肠癌新辅助放化疗后侧方淋巴结清扫术的临床观察[J]. 中华普外科手术学杂志(电子版), 2024, 18(04): 415-418.
[7] 宫向良, 刘征, 丁梅. 基于膜解剖D2+CME根治术治疗胃癌的近中期随访研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(03): 267-270.
[8] 魏微阳, 杨浩, 周川鹏, 王奇, 黄红星, 黄亚强. 纤维蛋白原与白蛋白比值及其列线图模型对非肌层浸润性膀胱癌患者电切术后复发的预测价值[J]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(03): 243-248.
[9] 俞国杰, 瓦热斯·先木西丁, 米尔扎提·麦麦提, 吴婷, 张洁祥. 复发性泌尿系结石成分变化及其影响因素分析[J]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(03): 259-265.
[10] 邱志东, 张杰, 薛鹏, 郑玲玲, 杨建桃, 赵海军, 陈双. 补片固定与否对腹股沟疝经腹腹膜前修补术后患者并发症的影响[J]. 中华疝和腹壁外科杂志(电子版), 2024, 18(04): 406-409.
[11] 邓万玉, 陈富, 许磊波. 肝硬化与非肝硬化乙肝相关性肝癌患者术后无复发生存比较及其影响因素分析[J]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 670-674.
[12] 周庆, 杨旭. 甲胎蛋白、纤维蛋白原与前白蛋白比值、癌胚抗原、D-二聚体对结肠癌术后复发的预测价值[J]. 中华消化病与影像杂志(电子版), 2024, 14(04): 301-305.
[13] 田娜, 韩飞天. 基于CT平扫影像组学模型与系统免疫炎症指数预测急性胰腺炎复发模型的建立[J]. 中华消化病与影像杂志(电子版), 2024, 14(04): 355-359.
[14] 徐清华, 张振林, 李浩. 清胰汤联合乌司他丁对急性胰腺炎患者肠道功能恢复及炎性因子水平的影响[J]. 中华消化病与影像杂志(电子版), 2024, 14(03): 253-257.
[15] 郭曌蓉, 王歆光, 刘毅强, 何英剑, 王立泽, 杨飏, 汪星, 曹威, 谷重山, 范铁, 李金锋, 范照青. 不同亚型乳腺叶状肿瘤的临床病理特征及预后危险因素分析[J]. 中华临床医师杂志(电子版), 2024, 18(06): 524-532.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号